Sung Jung
Nurse Practitioner · Honolulu, HINPI 1932537586
Payments from drug & device makers
Across 979 payments — averaging $29.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$7K
- AstraZeneca$5K
- AbbVie$4K
- Amgen$2K
- Boehringer Ingelheim$1K
- Amarin Pharma, Inc.$1K
- plus $8K from 27 others
What the payments were for
- Consulting fees$3,65413%
- Travel & lodging$1,5475%
- Food & beverage$22,93880%
- Education$3691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 83 | $7,302 |
| AstraZeneca | 131 | $4,593 |
| AbbVie | 178 | $3,978 |
| Amgen | 108 | $2,265 |
| Boehringer Ingelheim | 50 | $1,492 |
| Amarin Pharma, Inc. | 46 | $1,198 |
| GSK | 67 | $851 |
| Lilly USA, LLC | 42 | $841 |
| Astellas Pharma US Inc | 21 | $746 |
| Pfizer | 38 | $607 |
| Kowa Pharmaceuticals America, Inc. | 39 | $601 |
| Novo Nordisk | 27 | $598 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $519 |
| Galt Pharmaceuticals, LLC | 1 | $513 |
| Esperion Therapeutics, Inc. | 29 | $464 |
| Avanir Pharmaceuticals, Inc. | 23 | $399 |
| Arbor Pharmaceuticals, Inc. | 17 | $256 |
| Sanofi-aventis U.S. LLC | 11 | $214 |
| Otsuka America Pharmaceutical, Inc. | 9 | $205 |
| Nestle Healthcare Nutrition Inc. | 11 | $186 |
| Sanofi | 7 | $175 |
| Eisai Inc. | 5 | $96 |
| Gilead | 3 | $69 |
| Lundbeck LLC | 2 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Exact Sciences | 2 | $41 |
| Novartis | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Medicure Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,508 in reported general payments places this provider in the 95th percentile of 215 nurse practitioner providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 494 | $424,717 |
| FarxigaDapagliflozin Propanediol | 213 | $278,002 |
| MounjaroTirzepatide | 94 | $247,258 |
| CreonLipase/Protease/Amylase | 66 | $238,246 |
| ProliaDenosumab | 108 | $193,959 |
| KerendiaFinerenone | 95 | $177,923 |
| Diclofenac Epolamine | 137 | $153,594 |
| LinzessLinaclotide | 110 | $135,356 |
| TrulicityDulaglutide | 31 | $85,009 |
| EdarbiAzilsartan Medoxomil | 145 | $84,195 |
| RybelsusSemaglutide | 33 | $76,337 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 30 | $74,702 |
| OzempicSemaglutide | 32 | $69,893 |
| JardianceEmpagliflozin | 36 | $65,962 |
| LivaloPitavastatin Calcium | 69 | $60,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Tezspire, Lokelma, Breztri Aerosphere | $4,593 | $379,734285 claims |
| AbbVieCreon, Linzess | $3,978 | $373,602176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $841 | $332,267125 claims |
| AmgenProlia, Evenity (2 Syringes) | $2,265 | $268,661138 claims |
| BayerKerendia | $7,302 | $177,92395 claims |
| Novo NordiskRybelsus, Ozempic | $598 | $146,23065 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Tradjenta | $1,492 | $131,99683 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $256 | $108,092197 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix | $851 | $72,751214 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $601 | $60,08569 claims |
| Astellas Pharma US IncMyrbetriq | $746 | $55,11456 claims |
| PfizerEliquis | $607 | $27,68524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 nurse practitioner providers in Hawaii.
Other nurse practitioner in Honolulu
- Ashley SpringerHonolulu$43K
- Judy KoHonolulu$17K
- Bryce MontalboHonolulu$15K
- Rita AbreuHonolulu$9K
- Jinny ChingHonolulu$7K
- Nancy BanhHonolulu$6K
- Kelly FuruikeHonolulu$6K
- Qi ZhiHonolulu$5K
- Mio OsakiHonolulu$5K
- Amanda TanhchaleunHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.